丹纳赫第一季度超出预期，在经济动荡中表现出韧性

丹纳赫公司（纽约证券交易所股票代码：DHR）公布了强劲的第一季度业绩，超出了分析师的每股收益和收入预期。尽管收入同比下降 2.5% 至 58 亿美元，但丹纳赫调整后每股收益为 1.92 美元，展示了运营效率和成本管理有效性。该公司领先的产品组合和业务系统的执行为持续的业绩做出了贡献。然而，丹纳赫预计经济环境充满挑战，预计第二季度非公认会计准则核心收入将出现中个位数下降，反映出其谨慎的前景。

Danaher Surges Past Q1 Expectations, Demonstrating Resilience Amidst Economic Headwinds

丹纳赫第一季度业绩大幅超出预期，在经济逆风中展现出韧性

New York, April 2024 - Danaher Corporation (NYSE: DHR), a global behemoth in life sciences and diagnostics, has unveiled its financial performance for the first quarter of 2024, defying expectations and showcasing its unwavering strength.

纽约，2024 年 4 月 - 全球生命科学和诊断领域的巨头丹纳赫公司（纽约证券交易所股票代码：DHR）公布了 2024 年第一季度的财务业绩，超出预期，展示了其坚定不移的实力。

Despite a tumultuous economic climate, Danaher recorded a net income of $1.1 billion, translating to $1.45 per diluted common share. Notably, its non-GAAP diluted net earnings per common share reached $1.92 on an adjusted basis, far exceeding analysts' projections.

尽管经济环境动荡，但丹纳赫仍实现净利润 11 亿美元，相当于每股稀释普通股 1.45 美元。值得注意的是，其调整后的非公认会计原则稀释后每股普通股净利润达到1.92美元，远远超出分析师的预测。

Even as reported revenue dipped by 2.5% year-over-year to $5.8 billion, Danaher's operational prowess shone through. Non-GAAP core revenue experienced a modest 4.0% reduction, underscoring the company's ability to navigate challenging market conditions.

尽管报告收入同比下降 2.5% 至 58 亿美元，但丹纳赫的运营实力依然闪耀。非 GAAP 核心收入小幅下降 4.0%，突显该公司应对充满挑战的市场环境的能力。

Operating cash flow remained robust at $1.7 billion, while non-GAAP free cash flow surged to $1.4 billion, providing ample liquidity for strategic investments and shareholder returns.

运营现金流保持强劲，达到 17 亿美元，而非 GAAP 自由现金流飙升至 14 亿美元，为战略投资和股东回报提供充足的流动性。

Rainer M. Blair, President and CEO of Danaher, hailed the quarter's achievements, highlighting the positive trends in the bioprocessing business and market share gains in Cepheid's molecular diagnostics division. He attributed these successes to the company's leading portfolio and the meticulous execution of the Danaher Business System, which he believes will continue to drive long-term growth and meaningful contributions to healthcare.

丹纳赫总裁兼首席执行官 Rainer M. Blair 对本季度的成就表示赞赏，强调了生物加工业务的积极趋势以及 Cepheid 分子诊断部门的市场份额增长。他将这些成功归功于公司领先的产品组合和丹纳赫业务系统的精心执行，他相信这将继续推动长期增长并为医疗保健做出有意义的贡献。

Analysts Outpaced, Danaher's Execution Impresses

丹纳赫的执行力令人印象深刻，分析师领先

Analysts had cautiously predicted earnings per share (EPS) of $1.72 and revenue of $5.62 billion for the quarter. However, Danaher's adjusted EPS of $1.92 handily surpassed these expectations, demonstrating the company's operational efficiency and ability to generate higher-than-anticipated profitability. Similarly, the reported revenue of $5.8 billion exceeded market forecasts, signaling robust sales performance across its diversified portfolio.

分析师谨慎预测本季度每股收益 (EPS) 为 1.72 美元，营收为 56.2 亿美元。然而，丹纳赫调整后每股收益 1.92 美元轻松超出了这些预期，证明了该公司的运营效率和产生高于预期盈利能力的能力。同样，报告的 58 亿美元收入超出了市场预期，表明其多元化产品组合的销售业绩强劲。

These results underscore Danaher's adaptability and strategic focus amidst intense competition and economic uncertainty. The company's ability to deliver exceptional financial outcomes is a testament to its strong business segments and effective cost management.

这些结果凸显了丹纳赫在激烈的竞争和经济不确定性中的适应性和战略重点。该公司提供卓越财务成果的能力证明了其强大的业务部门和有效的成本管理。

Cautious Guidance for Q2, Reflecting Global Economic Challenges

第二季度谨慎指引，反映全球经济挑战

While Danaher's Q1 performance was commendable, the company adopted a more conservative tone when guiding for the second quarter and full year 2024. Acknowledging the persistent global economic uncertainty, the company anticipates a mid-single-digit decline in non-GAAP core revenue year over year for Q2 and a low-single-digit decline for the full year.

尽管丹纳赫第一季度的业绩值得称赞，但该公司在预测第二季度和 2024 年全年时采取了更为保守的基调。考虑到全球经济持续存在不确定性，该公司预计非 GAAP 核心收入同比将出现中个位数下降第二季度同比下降，全年同比下降个位数。

This guidance suggests that Danaher remains vigilant about potential market volatility and is prudently planning for the challenges that may lie ahead in the global economic landscape. Nonetheless, the company's strong foundation and proven track record of execution provide investors with confidence in its ability to weather any storms and emerge even stronger.

该指引表明，丹纳赫对潜在的市场波动保持警惕，并正在谨慎规划全球经济格局中可能面临的挑战。尽管如此，该公司坚实的基础和良好的执行记录让投资者对其抵御任何风暴并变得更加强大的能力充满信心。